Vol. 26, No. 2, 2004 (June)
	Content

CASPASES AND CANCER: MECHANISMS OF INACTIVATION AND NEW TREATMENT MODALITIES

Aleksei Philchenkov¹, Michael Zavelevich¹, Tadeusz J. Kroczak², Marek Los^2,3

¹R.E. Kavetsky Institute of Experimental Pathology, Oncology, and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine
²Manitoba Institute of Cell Biology, Cancer Care Manitoba, Winnipeg, R3E 0V9, Canada
³Institute of Experimental Dermatology, University of Munster, Munster, D-48149, Germany

Abstract. Elimination of superfluous or mutated somatic cells is provided by various mechanisms including apoptosis. Deregulation of apoptotic signaling pathways may contribute to oncogenesis. Aspartate specific cysteine proteases, termed caspases are the key effector molecules in apoptosis. The aim of this review is to summarize the various defects in caspase-dependent cell death machinery identified in the neoplastic cells. These include not only mutations, but also alterations of gene methylation, and altered mRNA stability. Among the molecules that we discuss are elements of the extrinsic death pathway like CD95 (APO-1/Fas), FADD, FLIPs, FLICE, other apical caspases, components of the intrinsic apoptotic pathway like Apaf-1, caspase-9, and modulators of apoptotic pathways like IAPs, Smac/DIABLO, OMI/HtrA2, and other apoptosis regulating proteins. We also discuss recent data on cancer-specific agents that target effector mechanisms of apoptosis. Particular emphasis is given to the prospects for combining cell suicide-activating approaches with classical cancer therapies.

Key Words: apoptosis, caspase, mutation, tumor cell, cancer patient, caspase activators, fusion proteins, cell-permeable peptides, anticancer drugs, gene therapy, siRNA, preclinical study.

Language:

[full text]